Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
42.86
+0.03 (+0.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics Inc
< Previous
1
2
3
4
5
Next >
34 Stocks Moving In Tuesday's Mid-Day Session
January 18, 2022
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares gained 37.2% to $6.75 after the company eeceived FDA Breakthrough Device Designation for the treatment of chronic chemo induced...
Via
Benzinga
FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program
January 18, 2022
The FDA has placed a clinical hold on Dyne Therapeutics Inc's (NASDAQ: DYN) investigational New Drug (IND) application to initiate a clinical trial of DYNE...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 12, 2022
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...
Via
Benzinga
Stocks Hitting New 52-Week Lows Today
January 03, 2022
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...
Via
Benzinga
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
October 01, 2021
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular...
Via
Benzinga
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
June 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,...
Via
Benzinga
Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies
May 14, 2021
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.